TipRanks
Advertisement
Advertisement

DE:0GO Stock Latest News

Thalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline
Company AnnouncementsThalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline
10d ago
Thalia Therapeutics Secures Chinese Patent for Lead AML Drug miRisten
PremiumCompany Announcements
Thalia Therapeutics Secures Chinese Patent for Lead AML Drug miRisten
11d ago
Thalia Therapeutics Advances Dual-Target RNA Cardiovascular Drug THAT-002
PremiumCompany Announcements
Thalia Therapeutics Advances Dual-Target RNA Cardiovascular Drug THAT-002
15d ago
Thalia Therapeutics Advances RNA Portfolio After Strategic Transformation
PremiumCompany Announcements
Thalia Therapeutics Advances RNA Portfolio After Strategic Transformation
25d ago
Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances
PremiumCompany Announcements
Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances
2M ago
Thalia Therapeutics Grants Major Director Option Package Tied to Share Price Targets
PremiumCompany AnnouncementsThalia Therapeutics Grants Major Director Option Package Tied to Share Price Targets
3M ago
Thalia Therapeutics Completes Sanmirna Deal and Enlarges Capital Base After AGM
Premium
Company Announcements
Thalia Therapeutics Completes Sanmirna Deal and Enlarges Capital Base After AGM
3M ago
Thalia Therapeutics Targets Clinical-Stage Growth With Sanmirna Deal and RNA Pipeline Push
Premium
Company Announcements
Thalia Therapeutics Targets Clinical-Stage Growth With Sanmirna Deal and RNA Pipeline Push
3M ago
Thalia Therapeutics Sets AGM to Vote on Sanmirna Acquisition and Fundraise
PremiumCompany Announcements
Thalia Therapeutics Sets AGM to Vote on Sanmirna Acquisition and Fundraise
4M ago
Thalia Therapeutics buys Sanmirna and raises £2.75m to fast-track AML RNA therapy
PremiumCompany Announcements
Thalia Therapeutics buys Sanmirna and raises £2.75m to fast-track AML RNA therapy
4M ago
Thalia Therapeutics pivots to RNA therapeutics as Nuvec platform advances toward clinic
PremiumCompany Announcements
Thalia Therapeutics pivots to RNA therapeutics as Nuvec platform advances toward clinic
4M ago
Thalia Therapeutics Showcases RNA Strategy in European Biotech Feature
PremiumCompany Announcements
Thalia Therapeutics Showcases RNA Strategy in European Biotech Feature
4M ago
Thalia Therapeutics Showcases Differentiated RNA Strategy and Cardiovascular Candidate
PremiumCompany AnnouncementsThalia Therapeutics Showcases Differentiated RNA Strategy and Cardiovascular Candidate
4M ago
Thalia Therapeutics CEO Outlines Strategic Pivot to High-Value RNA Therapies
Premium
Company Announcements
Thalia Therapeutics CEO Outlines Strategic Pivot to High-Value RNA Therapies
5M ago
Thalia Therapeutics Updates Registered Office in London
Premium
Company Announcements
Thalia Therapeutics Updates Registered Office in London
6M ago
N4 Pharma Rebrands as Thalia Therapeutics to Reflect RNA Therapeutics Focus
PremiumCompany Announcements
N4 Pharma Rebrands as Thalia Therapeutics to Reflect RNA Therapeutics Focus
7M ago
N4 Pharma Plans Rebrand to Thalia Therapeutics to Reflect RNA-Focused Strategy
PremiumCompany Announcements
N4 Pharma Plans Rebrand to Thalia Therapeutics to Reflect RNA-Focused Strategy
8M ago
N4 Pharma Rebrands as Thalia Therapeutics and Hires New CEO to Drive RNA Pivot
PremiumCompany Announcements
N4 Pharma Rebrands as Thalia Therapeutics and Hires New CEO to Drive RNA Pivot
8M ago
N4 Pharma Advances Nuvec® Platform with Strategic Collaborations and Patent Strengthening
PremiumCompany Announcements
N4 Pharma Advances Nuvec® Platform with Strategic Collaborations and Patent Strengthening
10M ago
N4 Pharma Advances Nuvec® Gene Delivery System with Key Collaborations and Patent Strengthening
PremiumCompany AnnouncementsN4 Pharma Advances Nuvec® Gene Delivery System with Key Collaborations and Patent Strengthening
10M ago
N4 Pharma Reports Strong Interim Results and Strategic Progress in 2025
Premium
Company Announcements
N4 Pharma Reports Strong Interim Results and Strategic Progress in 2025
1y ago
N4 Pharma Partners with University of Strathclyde to Advance Nuvec® Platform
Premium
Company Announcements
N4 Pharma Partners with University of Strathclyde to Advance Nuvec® Platform
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >